WO2020119701A1 - 一种维拉佐酮固体分散体及其制备方法 - Google Patents

一种维拉佐酮固体分散体及其制备方法 Download PDF

Info

Publication number
WO2020119701A1
WO2020119701A1 PCT/CN2019/124446 CN2019124446W WO2020119701A1 WO 2020119701 A1 WO2020119701 A1 WO 2020119701A1 CN 2019124446 W CN2019124446 W CN 2019124446W WO 2020119701 A1 WO2020119701 A1 WO 2020119701A1
Authority
WO
WIPO (PCT)
Prior art keywords
vilazodone
solid dispersion
carrier material
weight percentage
plasticizer
Prior art date
Application number
PCT/CN2019/124446
Other languages
English (en)
French (fr)
Inventor
方代龙
范露露
黄心
游劲松
黄芳芳
Original Assignee
广东东阳光药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东东阳光药业有限公司 filed Critical 广东东阳光药业有限公司
Priority to CN201980080339.8A priority Critical patent/CN113164394B/zh
Publication of WO2020119701A1 publication Critical patent/WO2020119701A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the field of biomedicine, in particular to a solid dispersion of vilazodone and a preparation method and application thereof.
  • Verazodone is the first indole alkylamine antidepressant, which belongs to selective serotonin reuptake inhibitors and 5-HT1A receptor partial agonists.
  • the tablets After oral administration, the tablets are mainly absorbed in the small intestine, and the peak time (T max ) of the plasma drug concentration is 4 to 5 hours.
  • T max peak time
  • the solubility under the environmental conditions of gastric juice (pH 1.2) and intestinal juice (pH 4.5-6.8) is poor, and only has a certain solubility in an environment around pH 3.1, so Its fasting oral bioavailability is low, resulting in The bioavailability is extremely low when taken on an empty stomach, and it is difficult to meet the clinical treatment needs. therefore,
  • the instructions clearly indicate that the drug must be taken with food; under eating conditions, the pH value of the human gastric juice is about 3.1, and can delay the gastric emptying of the drug, which ultimately makes Oral bioavailability under eating conditions can reach about 72%.
  • vilazodone hydrochloride In order to improve the solubility of vilazodone hydrochloride, the prior art discloses that it is prepared as an amorphous substance, which can increase the solubility.
  • IN2012CH03815A patent discloses a solid dispersion prepared by vilazodone hydrochloride and copovidone (S-630) or povidone (PVP-K30), X-ray diffraction (XRD) pattern shows that vilazodone hydrochloride is indefinite
  • S-630 copovidone
  • PVP-K30 povidone
  • XRD X-ray diffraction
  • Patent CN104983711 discloses a solid dispersion prepared by vilazodone hydrochloride and povidone (PVP) or polyethylene glycol (PEG). After dissolving the carrier material and vilazodone hydrochloride in an ethanol solution, it is dried under reduced pressure. A solid is obtained. Because the solubility of vilazodone hydrochloride is better than the free base of vilazodone, the prior art uses vilazodone hydrochloride to prepare an amorphous solid dispersion to further improve the solubility. In addition, vilazodone hydrochloride has a high melting point (290°C), and it is not suitable to prepare an amorphous solid dispersion by the melt method or hot melt extrusion method.
  • PVP povidone
  • PEG polyethylene glycol
  • the solvent method is used to prepare vilazodone hydrochloride. It is dissolved in an organic solvent with the carrier material, and then dried to obtain a solid substance.
  • organic solvents are not easy to remove in industrial production and easily cause pollution to the environment; in addition, due to the use of large amounts of organic solvents, there is a greater hidden danger to the health and safety of factory operators, and industrial production equipment Explosion-proof devices are required, and the cost is higher.
  • the present invention provides a solid dispersion of vilazodone, the solid dispersion comprising vilazodone, a carrier material and a plasticizer,
  • the vilazodone is vilazodone free base.
  • solubility of vilazodone free base is significantly lower than that of vilazodone hydrochloride, the present inventors have unexpectedly found that an amorphous solid dispersion prepared with vilazodone free base can significantly increase the in vitro solubility and in vivo of vilazodone bioavailability.
  • a solid dispersion of vilazodone is proposed, the solid dispersion comprising vilazodone, a carrier material and a plasticizer.
  • the carrier material is a water-soluble carrier material, including but not limited to povidone (PVP), copovidone, hydroxypropyl methylcellulose (HPMC), hypromellose succinate (HPMC -CAS), hydroxypropyl cellulose (HPC), cellulose acetate phthalate (CAP), hypromellose phthalate (HPMCP), polypropylene resin (Eudragit L, Eudragit S) or Multiple.
  • PVP povidone
  • HPMC hydroxypropyl methylcellulose
  • HPMC -CAS hypromellose succinate
  • HPPC hydroxypropyl cellulose
  • CAP cellulose acetate phthalate
  • HPPMCP hypromellose phthalate
  • Polypropylene resin Eudragit L, Eudragit S
  • the present invention examines the carrier materials of povidone, copovidone, hydroxypropyl methyl cellulose, and hypromellose succinate.
  • vilazodone was dispersed in the carrier material in an amorphous state, and its dissolution rate in simulated small intestinal fluid (pH 6.8 medium) was significantly higher than that of the reference Specific preparation
  • copovidone or hydroxypropyl methylcellulose (HPMC-LV) is used, the dissolution platform of the prepared solid dispersion reaches more than 50%.
  • the present invention also examines the ratio of vilazodone to carrier material.
  • the weight ratio of vilazodone to carrier material is not greater than 1:2, the prepared solid dispersion dissolves in vitro significantly higher than the reference preparation Considering the safety problems brought about by a large number of excipients and the difficulty of preparation of later preparations, the weight ratio of vilazodone to carrier material in the present invention is 1:2 to 1:7, or 1:4 to 1:6.
  • the weight ratio of vilazodone to carrier material is 1:2 to 1:4; in some embodiments, the weight ratio of vilazodone to carrier material is 1:2 to 1:6; In some embodiments, the weight ratio of vilazodone to carrier material is 1:4 to 1:7; in some embodiments, the weight ratio of vilazodone to carrier material is 1:6 to 1:7. In some embodiments, the weight ratio of vilazodone to carrier material is 1:2, 1:3, 1:4, 1:5, 1:6, or 1:7.
  • the solid dispersion provided by the present invention further includes a plasticizer.
  • the plasticizer By adding the plasticizer, the glass transition temperature (Tg) of the entire material system can be Significantly reduced, making the hot melt extrusion process feasible, and easy to obtain amorphous solid dispersion.
  • the solid dispersion of vilazodone further includes a plasticizer
  • the plasticizer includes but is not limited to the following categories:
  • Polyoxyethylene alkyl ethers such as polyoxyethylene (3) lauryl ether, polyoxyethylene (5) cetyl ether, polyoxyethylene (2) stearyl ether, polyoxyethylene (5) stearyl ether; polyoxyethylene Vinyl alkyl aryl ethers, such as polyoxyethylene (2) nonylphenyl ether, polyoxyethylene (3) nonylphenyl ether, polyoxyethylene (4) nonylphenyl ether, polyoxyethylene (3 ) Octyl phenyl ether; polyethylene glycol glycerides, such as PEG-200 monolaurate, PEG-200 dilaurate, PEG-300 dilaurate, PEG-400 dilaurate, PEG -300 distearate, PEG-300 dioleate; alkylene glycol fatty acid monoesters, such as propylene glycol monolaurate; sucrose fatty acid esters, such as sucrose monostearate, sucrose distearate Esters, sucrose monolaurate,
  • the present invention is based on Span-20, polyethylene glycol, polyoxyethylene hydrogenated castor oil, caprylic capric acid polyethylene glycol glyceride, poloxamer, alpha-tocopherol polyethylene glycol Plasticizers such as succinate were investigated.
  • the solid dispersion of vilazodone prepared with different plasticizers was significantly higher in vitro than the reference preparation
  • the plasticizer is polyoxyethylene 40 hydrogenated castor oil
  • the prepared vilazodone solid dispersion dissolves a higher reference preparation in vitro
  • the present invention further investigates the proportion of plasticizer.
  • the weight percentage of plasticizer is not less than 2.5%, the dissolution rate of the prepared vilazodone solid dispersion in vitro is significantly higher than that of the plasticizer.
  • the weight percentage of the plasticizer is 2.5% to 15.0%; in some embodiments, the weight percentage of the plasticizer is 5.0% to 10.0%. In some examples, the weight percentage of the plasticizer is 2.5% to 5.0%; in some examples, the weight percentage of the plasticizer is 2.5% to 10.0%; in some examples, the plasticizer The percentage by weight is from 5.0% to 15.0%; in some examples, the percentage by weight of the plasticizer is from 10.0% to 15.0%. In some examples, the weight percentage of the plasticizer is 2.5%, 5.0%, 10.0%, or 15.0%.
  • the present invention unexpectedly discovered that after adding an acidic reagent to the prescription, the dissolution of the prepared vilazodone solid dispersion in the simulated small intestine fluid (pH 6.8) will be further improved, significantly higher than Reference preparation
  • the acidic reagent of the present invention includes but is not limited to one or more of fumaric acid, citric acid monohydrate, citric acid, tartaric acid, succinic acid, and stearic acid.
  • the acidic reagent includes one or more selected from fumaric acid, citric acid monohydrate, citric acid, or L-tartaric acid; in some embodiments, the acidic reagent is citric acid or Citric acid monohydrate.
  • the present invention further investigates the proportion of acidic reagents.
  • the weight percentage of acidic reagents is not less than 2.5%, the dissolution rate of the prepared vilazodone solid dispersion in vitro is significantly higher than that of the reference preparation
  • the weight percentage of the acidic reagent is 2.5%-25.0%; in some embodiments, the weight percentage of the acidic reagent is 5.0%.
  • the weight percentage of the acidic reagent is 2.5% to 5.0%; in some embodiments, the weight percentage of the acidic reagent is 2.5% to 10.0%; in some embodiments, the acidic reagent The weight percentage is 2.5% to 15.0%; in some embodiments, the acid reagent weight percentage is 5.0% to 10.0%; in some embodiments, the acid reagent weight percentage is 5.0% to 15.0%; In some embodiments, the weight percentage of the acidic reagent is 5.0% to 25.0%; in some embodiments, the weight percentage of the acidic reagent is 10.0% to 15.0%; in some embodiments, the acidic reagent The weight percentage is 10.0%-25.0%; in some embodiments, the weight percentage of the acidic reagent is 15.0%-25.0%. In some examples, the weight percentage of the acidic reagent is 2.5%, 5.0%, 10.0%, 15.0%, or 25.0%.
  • a solid dispersion of vilazodone comprising vilazodone free base, copovidone, polyoxyethylene 40 hydrogenated castor oil, and citric acid monohydrate.
  • the amorphous solid dispersion prepared by free base can significantly increase the in vitro solubility and in vivo bioavailability of vilazodone.
  • the weight ratio of vilazodone to copovidone is 1:3 to 1:6. In some embodiments, the weight ratio of vilazodone to copovidone is 1:3 to 1:4; in some embodiments, the weight ratio of vilazodone to copovidone is 1:3 to 1: 5; in some embodiments, the weight ratio of vilazodone to copovidone is 1:4 to 1:5; in some embodiments, the weight ratio of vilazodone to copovidone is 1:4 to 1:6; in some embodiments, the weight ratio of vilazodone to copovidone is 1:5 to 1:6. In some embodiments, the weight ratio of vilazodone to copovidone is 1:3, 1:4; 1:5, or 1:6.
  • the weight percentage of the polyoxyethylene 40 hydrogenated castor oil is 2.5% to 15.0%, or 5.0% to 10.0%. In some examples, the weight percentage of the polyoxyethylene 40 hydrogenated castor oil is 2.5% to 5.0%; in some examples, the weight percentage of the polyoxyethylene 40 hydrogenated castor oil is 2.5% to 10.0%; in some In an example, the weight percentage of the polyoxyethylene 40 hydrogenated castor oil is 5.0% to 15.0%; in some examples, the weight percentage of the polyoxyethylene 40 hydrogenated castor oil is 10.0% to 15.0%. In some embodiments, the weight percent of polyoxyethylene 40 hydrogenated castor oil is 2.5%, 5.0%, 10.0%, or 15.0%.
  • the weight percentage of citric acid monohydrate is 2.5% to 20.0%. In some embodiments, the weight percent of citric acid monohydrate is 2.5% to 5.0%; in some embodiments, the weight percent of citric acid monohydrate is 2.5% to 10.0%; in some embodiments, The weight percentage of the citric acid monohydrate is 5.0% to 10.0%; in some embodiments, the weight percentage of the citric acid monohydrate is 5.0% to 20.0%; in some embodiments, the citric acid monohydrate The weight percentage is 10.0% ⁇ 20.0%. In some embodiments, the weight percentage of citric acid monohydrate is 2.5%, 5.0%, 10.0%, or 20.0%.
  • a method for preparing the above solid dispersion of vilazodone there is provided a method for preparing the above solid dispersion of vilazodone.
  • the specific plan is as follows:
  • a preparation method of the above-mentioned vilazodone solid dispersion includes the following steps: Weighing vilazodone, carrier material and other materials according to the mixing ratio, mixing uniformly, adding to a hot-melt extruder, extruding the mixture, after cooling After crushing and sieving, the solid dispersion of vilazodone is obtained.
  • the extrusion temperature of the hot melt extruder is 155°C to 180°C; in some embodiments, the extrusion temperature of the hot melt extruder is 165°C to 175°C.
  • vilazodone solid dispersion in the preparation of vilazodone formulations.
  • the solid dispersion of vilazodone can be further prepared into granules, powders, dry suspensions, tablets or capsules with other pharmaceutically acceptable excipients; in some embodiments, the tablets are coated tablets .
  • the pharmaceutically acceptable auxiliary materials include but are not limited to the following:
  • Fillers such as lactose, sucrose, fructose, fructooligosaccharides, glucose, maltose, powdered sugar and other sugars, D-mannitol, erythritol, xylitol and other sugar alcohols, corn starch, potato starch, rice starch ,
  • Some starch such as ⁇ starch, cellulose such as microcrystalline cellulose, inorganic salts such as calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.
  • disintegrants such as starch, microcrystalline cellulose, carboxymethyl cellulose calcium, Croscarmellose sodium, crospovidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, etc.
  • lubricants such as magnesium stearate, calcium stearate, stearic fumaric acid Sodium, stearic acid, talc, polyethylene glycol, sucrose fatty acid ester, micronized silica gel.
  • the present invention further compresses the prepared solid dispersion of vilazodone into tablets, and examines its pharmacokinetic properties in vivo.
  • the results show that the solid dispersion composition of vilazodone provided by the present invention can significantly improve the bioavailability of vilazodone under fasting conditions, and further, it can significantly eliminate the effects of food effects, so that under fasting and eating conditions It is equivalent when taken, and can be taken on an empty stomach and eating conditions, which significantly improves the convenience of patients taking medication and improves patient compliance. This is for patients with severe depression who require long-term medication and often have anorexia and suicidal tendencies. It has great clinical significance.
  • the present invention also conducted a stability investigation on the prepared vilazodone solid dispersion. After being placed under accelerated conditions (40°C, 75% RH) for 3 months, the prepared vera The solid dispersion of adjuvant is still in an amorphous state, and there is no significant change in dissolution rate in vitro, indicating that the solid dispersion of vilazodone provided by the present invention has good stability, and is suitable for the development of solid dispersion preparation of vilazodone and its clinical application .
  • LC-MS-MS refers to liquid-mass spectrometry
  • XRD refers to X-ray diffraction
  • PVP povidone
  • VA64 copovidone
  • HPMC hydroxypropyl methylcellulose
  • Labrasol caprylic capric acid polyethylene glycol glyceride
  • Cremophor RH40 polyoxyethylene 40 hydrogenated castor oil
  • T-80 refers to vomiting Wen-80
  • F68 refers to Poloxamer 188
  • S-20 refers to Span-20
  • TPGS refers to (D) ⁇ -tocopherol polyethylene glycol 1000 succinate.
  • PEG polyethylene glycol
  • Soluplus refers to polyethylene glycol/vinyl caprolactam/vinyl acetate copolymer
  • HPMCAS hypromellose acetate succinate
  • HPC hydroxypropyl cellulose
  • AUC refers to the area under the blood drug concentration-time curve
  • C max refers to the peak blood drug concentration
  • M refers to moles
  • h refers to hours
  • g refers to grams
  • mm refers to millimeters
  • ⁇ m refers to micrometers
  • nm refers to nanometers
  • ⁇ l refers to microliters
  • min refers to minutes
  • °C refers to degrees Celsius
  • mg refers to milligrams
  • mL refers to milliliters
  • rpm refers to revolutions per minute .
  • Fig. 1 (2) XRD pattern of the solid dispersion of vilazodone prepared by different carrier materials in Example 1 (2).
  • Figure 3 XRD pattern of the solid dispersion of vilazodone prepared in Example 3 (1) with different acid reagents.
  • Fig. 4 XRD pattern of the solid dispersion of vilazodone prepared with different ratios of VA64 in Example 5 (1).
  • Figure 6 Comparative Example 1 XRD pattern of vilazodone hydrochloride solid dispersion.
  • Hydroxypropyl methylcellulose succinate (HPMCAS-LF and HPMCAS-MF) was purchased from American Ashland company; polyethylene glycol/vinyl caprolactam/vinyl acetate copolymer (Soluplus), povidone (PVP-K12 ) was purchased from BASF, Germany; copovidone (VA64) was purchased from BASF, Germany; hydroxypropyl methyl cellulose (HPMC-E5 and HPMC-LV15) was purchased from Ashland; hydroxypropyl cellulose (HPC) was purchased from Cao Da Company of Japan.
  • Tween-80 T-80
  • sodium dodecyl sulfate SDS
  • poloxamer 188 F68
  • poloxamer 477 P477)
  • span-20 S-20
  • polyoxygen Ethylene 40 hydrogenated castor oil Cremophor RH40
  • polyoxyethylene 35 castor oil Cremophor EL
  • caprylic capric acid polyethylene glycol glyceride Labrasol
  • Polyethylene glycol laurate (Gelucire 44/14), polyethylene glycol laurate (Gelucire 50/13)
  • TPGS ⁇ -tocopherol polyethylene glycol 1000 succinate
  • the method for determining the content of vilazodone is high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • the specific conditions are: chromatographic conditions: the detection wavelength is UV 242nm, the chromatographic column is kromasil 100-5 C18 (4.6mm ⁇ 150mm, 5 ⁇ m), and the mobile phase is The pH 6.0 of 0.02M dipotassium hydrogen phosphate and acetonitrile is 54:46 (V/V), the flow rate is 1.0 ml/min, the injection volume is 10 ⁇ l, and the running time reaches 4.5 min.
  • composition Prescription-1 Prescription-2 Prescription-3 Prescription-4 Vilazodone 10g 10g 10g Material type VA64 PVP-K12 HPMCAS-MF HPMC-LV15 Material usage 60g 60g 60g 60g Poloxamer 188 5g 5g 5g 5g
  • composition Prescription-5 Prescription-6 Prescription-7
  • composition Prescription-8 Prescription-9 Prescription-10 Prescription-11 Prescription-12 Prescription-13
  • HPMCSA-LF, plasticizer and vilazodone powder were weighed, mixed and mixed, added to the extruder, hot melt extruded (extrusion temperature 175°C, screw speed 150rpm), collected The extrudate was crushed by a crusher and passed through a 60 mesh sieve to obtain hot melt powder.
  • Hot melt extruded extrusion temperature 175°C, screw speed 150rpm
  • the extrudate was crushed by a crusher and passed through a 60 mesh sieve to obtain hot melt powder.
  • composition Prescription-14 Prescription-15 Prescription-16 Prescription-17
  • Vilazodone 10g 10g 10g HPMCAS-LF 60g 60g 60g 60g Plasticizer F68 Labrasol TPGS RH40 Dosage 5g 5g 5g 5g
  • composition Prescription-18 Prescription-19 Prescription-20 Prescription-21 Prescription-22 Prescription-23 Prescription-24 Vilazodone 10g 10g 10g 10g 10g 10g 10g VA64 60g 60g 60g 60g 60g —— —— PVP-12 —— —— —— —— —— 60g —— HPMC-LV15 —— —— —— ———————— 60g F68 5g 5g 5g 5g —— 5g 5g Span20 ———— ——————————————————— Acid reagent type Fumaric acid Citric acid monohydrate L-tartaric acid Succinic acid Citric acid monohydrate Citric acid monohydrate Citric acid monohydrate Citric acid monohydrate Acid reagent dosage 4g 4g 4g 4g 4g 4g 4g 4g 4g 4g
  • composition Prescription-25 Prescription-26 Prescription-27 Prescription-28 Prescription-29
  • Vilazodone 10g 10g 10g 10g 10g VA64 60g 60g 60g 60g 60g RH40 5g 5g 5g 5g Citric acid monohydrate 2g 4g 8g 14g 25g
  • composition Prescription-30 Prescription-31 Prescription-32 Prescription-33
  • Vilazodone 10g 10g 10g VA64 60g 60g 60g 60g RH40 2g 5g 9g 13g Citric acid monohydrate 4g 4g 4g 4g
  • composition Prescription-34 Prescription-35 Prescription-36 Prescription-37 Prescription-38 Prescription-39
  • composition Prescription-40 Prescription-41 Prescription-42 Vilazodone 10g 10g 10g VA64 30g 40g 48g HPMC-LV15 30g 10g 12g RH40 5g 5g 5g
  • composition Prescription-43 Prescription-44 Prescription-45 Vilazodone 10g 10g 10g VA64 60g 60g 60g RH40 5g 5g 5g Citric acid monohydrate 14g 14g 14g Hot melt extrusion temperature 175°C 165°C 155°C
  • composition Prescription-46 Prescription-47 Prescription-48 Vilazodone hydrochloride 15g 15g 15g VA64 60g —— 60g Soluplus —— 60g 30g Poloxamer 188 5g 5g 5g
  • the hot-melt extruded powder of prescription 18 is selected as the raw material, and the materials are weighed according to Table 24 and mixed evenly; the total mixed materials are passed through a 40-mesh sieve and directly compressed to obtain vilazodone hydrochloride tablets.
  • the pharmacokinetic test of Beagel dogs was investigated using the above-mentioned vilazodone hydrochloride tablets (10 mg specification).
  • Six male, healthy adult Beagle dogs with a body weight ranging from 15 to 20 kg were randomly divided into two groups for a double-crossover, two-cycle test to examine self-developed vilazodone tablets (10 mg) on an empty stomach and eat (high fat , High-calorie food) pharmacokinetic properties.
  • whole blood was taken at 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 24h; place the whole blood in a centrifuge tube containing K 2 EDTA anticoagulant, Centrifuge at 3500 rpm for 10 minutes at 4°C, collect the upper plasma, and store at -70°C until testing.
  • Table 25 reference preparation Please refer to priority patent WO2018082557A1 for PK data in animals.
  • the ratio values of Cmax and AUC are calculated according to this formula. After the ratio values of each animal are added, the sum is divided by the number of test animals to obtain the average value. If the average Ratio is in the range of about 70% to about 143%, it can be determined that the dosage form has no food effect, and it is equivalent when taken with an empty stomach. That is to say, whether the dosage form is taken under eating or fasting conditions, Have basically the same bioavailability and efficacy.
  • the solid dispersion formulation of vilazodone provided by the present invention can significantly improve the bioavailability of vilazodone when taken on an empty stomach, eliminating the effects of food, and can be taken under both fasting and eating conditions, which significantly improves the patient's medication Convenience and improve patient compliance, which is of great clinical significance for patients with severe depression who require long-term medication and are often accompanied by loss of appetite and suicidal tendencies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种维拉佐酮固体分散体及其制备方法和用途，所述固体分散体包含活性成分维拉佐酮游离碱、聚合物材料和增塑剂；所述固体分散体由热熔挤出方法制得，且维拉佐酮以非结晶态存在于固体分散体中；该固体分散体能显著提高维拉佐酮的溶解度和体外溶出度，从而显著增加其口服生物利用度；所述固体分散体可用于制备维拉佐酮的相关制剂。

Description

一种维拉佐酮固体分散体及其制备方法 技术领域
本发明涉及生物医药领域，具体涉及一种维拉佐酮固体分散体及其制备方法和应用。
背景技术
维拉佐酮是第一个吲哚烷基胺类抗抑郁药，属于选择性5-羟色胺再摄取抑制剂和5-HT1A受体部分激动剂。美国食品药品管理局(FDA)于2011年1月21日批准盐酸维拉佐酮片剂(商品名
Figure PCTCN2019124446-appb-000001
)用于治疗重度抑郁症。
Figure PCTCN2019124446-appb-000002
片剂口服给药后，主要在小肠部位吸收，其血浆药物浓度达峰时间(T max)为4～5h。然而，由于盐酸维拉佐酮溶解度低，在胃液(pH1.2)和肠液(pH4.5～6.8)环境条件下的溶解度均较差，只有在pH3.1左右的环境中有一定溶解度，故其空腹口服生物利用度较低，导致
Figure PCTCN2019124446-appb-000003
在空腹服用时生物利用极低，难以满足临床治疗需求。因此，
Figure PCTCN2019124446-appb-000004
说明书中明确指出该药物必须与食物同服；在进食条件下，人体胃液pH值约为3.1，且可延缓药物的胃排空，最终使得
Figure PCTCN2019124446-appb-000005
进食条件下的口服生物利用度可达到72％左右。
为了提高盐酸维拉佐酮的溶解度，现有技术公开了将其制备成无定型物，可增加溶解度。IN2012CH03815A专利公开了盐酸维拉佐酮与共聚维酮(S-630)或聚维酮(PVP-K30)制备的固体分散体，X-射线衍射(XRD)图谱显示盐酸维拉佐酮以无定形态存在于载体材料中，但文献中并未给出所制备的盐酸维拉佐酮固体分散体的溶解度或体外溶出度，其在体内是否能增加盐酸维拉佐酮的生物利用度也并不清楚。专利CN104983711公开了盐酸维拉佐酮与聚维酮(PVP)或聚乙二醇(PEG)制备的固体分散体，其将载体材料和盐酸维拉佐酮溶解于乙醇溶液后，减压干燥，得到固体物。由于盐酸维拉佐酮溶解性好于维拉佐酮游离碱，现有技术均采用盐酸维拉佐酮制备成无定型固体分散体以进一步提高溶解度。此外，盐酸维拉佐酮熔点较高(290℃)，不宜采用熔融法或热熔挤出法制备成无定型的固体分散体，现有技术中均采用溶剂法制备，将盐酸维拉佐酮与载体材料溶于有机溶剂中，再干燥，得到固体物质。然而，这些大量的有机溶剂在工业化生产中不易除干净，且容易对环境造成污染；此外，由于大量有机溶剂的使用，其对工厂操作人员的健康和安全存在较大的隐患，且工业生产设备需要配备防爆装置，成本较高。
发明内容
为了解决维拉佐酮溶解度差导致的空腹生物利用度较低问题，本发明提供了一种维拉佐酮固体分散体， 所述固体分散体包含维拉佐酮、载体材料和增塑剂，所述维拉佐酮为维拉佐酮游离碱。虽然维拉佐酮游离碱的溶解度显著低于盐酸维拉佐酮，但本发明意外的发现采用维拉佐酮游离碱制备的无定型固体分散体能显著的增加维拉佐酮的体外溶解度和体内生物利用度。
发明的第一方面，提出了一种维拉佐酮固体分散体，所述固体分散体包含维拉佐酮、载体材料和增塑剂。
本发明中，所述载体材料为水溶性载体材料，包括但不限于聚维酮(PVP)、共聚维酮、羟丙基甲基纤维素(HPMC)、羟丙甲纤维素琥珀酸酯(HPMC-CAS)、羟丙基纤维素(HPC)、醋酸纤维素酞酸酯(CAP)、羟丙甲纤维素酞酸酯(HPMCP)、聚丙烯树脂(Eudragit L、Eudragit S)中的一种或多种。
在一些实施例中，本发明对聚维酮、共聚维酮、羟丙基甲基纤维素、羟丙甲纤维素琥珀酸酯载体材料进行了考察。结果发现，在采用上述载体材料制备的固体分散体中，维拉佐酮以无定型态分散于载体材料中，且其在模拟小肠液(pH6.8介质)中的溶出度显著高于参比制剂
Figure PCTCN2019124446-appb-000006
尤其采用共聚维酮或羟丙基甲基纤维素(HPMC-LV)时，所制备的固体分散体溶出平台达到了50％以上。
在一些实施例中，本发明还对维拉佐酮与载体材料的比例进行了考察。当维拉佐酮与载体材料的重量比不大于1:2时，所制备的固体分散体体外溶出显著高于参比制剂
Figure PCTCN2019124446-appb-000007
考虑到大量辅料带来的安全性问题以及后期制剂制备的困难，本发明中维拉佐酮与载体材料的重量比为1:2～1:7，或者为1:4～1:6。在一些实施例中，维拉佐酮与载体材料的重量比为1:2～1:4；在一些实施例中，维拉佐酮与载体材料的重量比为1:2～1:6；在一些实施例中，维拉佐酮与载体材料的重量比为1:4～1:7；在一些实施例中，维拉佐酮与载体材料的重量比为1:6～1:7。在一些实施例中，维拉佐酮与载体材料的重量比为1:2，1:3，1:4，1:5，1:6，或者1:7。
由于维拉佐酮熔点较高，热熔挤出工艺制备成无定型的固体分散体具有较大的挑战。因此，为了得到无定型态的维拉佐酮固体分散体，本发明提供的固体分散体中还包括增塑剂，通过加入增塑剂后，整个物料体系的玻璃化转变温度(Tg)可以大幅度降低，使热熔挤出工艺可行性较好，且易得到无定型态的固体分散体。
根据本发明的实施例，所述维拉佐酮固体分散体还包括增塑剂，所述增塑剂包括但不限于以下几类：
聚氧乙烯烷基醚类，例如聚氧乙烯(3)月桂醚、聚氧乙烯(5)鲸蜡醚、聚氧乙烯(2)硬脂醚、聚氧乙烯(5)硬脂醚；聚氧乙烯烷基芳基醚类，例如聚氧乙烯(2)壬基苯基醚、聚氧乙烯(3)壬基苯基醚、聚氧乙烯(4)壬基苯基醚、聚氧乙烯(3)辛基苯基醚；聚乙二醇甘油酸酯类，例如PEG-200单月桂酸酯、PEG-200二月桂酸酯、PEG-300二月桂酸酯、PEG-400二月桂酸酯、PEG-300二硬脂酸酯、PEG-300二油酸酯；亚烷基二醇脂肪酸单酯，例如丙二醇单月桂酸酯；蔗糖脂肪酸酯类，例如蔗糖单硬脂酸酯、蔗糖二硬脂酸酯、蔗糖单月桂酸酯、蔗糖二月桂酸酯；脱水山梨醇脂肪酸单酯类，例如脱水山梨醇单月桂酸酯、脱水山梨醇单油 酸酯、脱水山梨醇单棕榈酸酯、脱水山梨醇硼旨酸酯，或一种或多种上述的混合物。
在一些实施例中，本发明分别对司盘-20、聚乙二醇、聚氧乙烯氢化蓖麻油、辛酸癸酸聚乙二醇甘油酯、泊洛沙姆、α-生育酚聚乙二醇琥珀酸盐等增塑剂进行了考察。采用不同增塑剂制备的维拉佐酮固体分散体的体外溶出均显著高于参比制剂
Figure PCTCN2019124446-appb-000008
当增塑剂为聚氧乙烯40氢化蓖麻油时，所制备的维拉佐酮固体分散体的体外溶出更高参比制剂
Figure PCTCN2019124446-appb-000009
在一些实施例中，本发明进一步地对增塑剂的比例进行了考察，当增塑剂的重量百分比不小于2.5％时，所制备的维拉佐酮固体分散体体外溶出度显著高于参比制剂
Figure PCTCN2019124446-appb-000010
在一些实施方式中，所述增塑剂的重量百分比为2.5％～15.0％；在一些实施方式中，所述增塑剂的重量百分比为5.0％～10.0％。在一些示例中，所述增塑剂的重量百分比为2.5％～5.0％；在一些示例中，所述增塑剂的重量百分比为2.5％～10.0％；在一些示例中，所述增塑剂的重量百分比为5.0％～15.0％；在一些示例中，所述增塑剂的重量百分比为10.0％～15.0％。在一些示例中，所述增塑剂的重量百分比为2.5％，5.0％，10.0％，或者15.0％。
在一些实施例中，本发明意外的发现，处方中加入酸性试剂后，所制备的维拉佐酮固体分散体在模拟小肠液(pH6.8)中的溶出度将进一步地提高，显著高于参比制剂
Figure PCTCN2019124446-appb-000011
本发明所述的酸性试剂包括但不限于富马酸、一水柠檬酸、柠檬酸、酒石酸、琥珀酸、硬脂酸中的一种或多种。在一些实施方式中，所述酸性试剂包括选自富马酸、一水柠檬酸、柠檬酸或L-酒石酸中的一种或多种；在一些实施方式中，所述酸性试剂为柠檬酸或一水柠檬酸。
在一些实施例中，本发明进一步对酸性试剂的比例进行了考察，当酸性试剂的重量百分比不小于2.5％时，所制备的维拉佐酮固体分散体体外溶出度显著高于参比制剂
Figure PCTCN2019124446-appb-000012
根据本发明的实施例，所述酸性试剂的重量百分比为2.5％～25.0％；在一些实施例中，酸性试剂的重量百分比为5.0％。在一些实施例中，所述酸性试剂的重量百分比为2.5％～5.0％；在一些实施例中，所述酸性试剂的重量百分比为2.5％～10.0％；在一些实施例中，所述酸性试剂的重量百分比为2.5％～15.0％；在一些实施例中，所述酸性试剂的重量百分比为5.0％～10.0％；在一些实施例中，所述酸性试剂的重量百分比为5.0％～15.0％；在一些实施例中，所述酸性试剂的重量百分比为5.0％～25.0％；在一些实施例中，所述酸性试剂的重量百分比为10.0％～15.0％；在一些实施例中，所述酸性试剂的重量百分比为10.0％～25.0％；在一些实施例中，所述酸性试剂的重量百分比为15.0％～25.0％。在一些示例中，所述酸性试剂的重量百分比为2.5％，5.0％，10.0％，15.0％，或者25.0％。
本发明第二方面，具体提供了一种维拉佐酮固体分散体，包含维拉佐酮游离碱、共聚维酮、聚氧乙烯40氢化蓖麻油和一水柠檬酸，所述维拉佐酮游离碱制备的无定型固体分散体能显著的增加维拉佐酮的体外溶解度和体内生物利用度。
所述维拉佐酮固体分散体，维拉佐酮与共聚维酮的重量比为1:3～1:6。在一些实施方式中，维拉佐酮与 共聚维酮的重量比为1:3～1:4；在一些实施方式中，维拉佐酮与共聚维酮的重量比为1:3～1:5；在一些实施方式中，维拉佐酮与共聚维酮的重量比为1:4～1:5；在一些实施方式中，维拉佐酮与共聚维酮的重量比为1:4～1:6；在一些实施方式中，维拉佐酮与共聚维酮的重量比为1:5～1:6。在一些实施例中，维拉佐酮与共聚维酮的重量比为1:3，1:4；1:5，或者1:6。
所述维拉佐酮固体分散体，所述聚氧乙烯40氢化蓖麻油的重量百分比为2.5％～15.0％，或者为5.0％～10.0％。在一些示例中，所述聚氧乙烯40氢化蓖麻油的重量百分比为2.5％～5.0％；在一些示例中，所述聚氧乙烯40氢化蓖麻油的重量百分比为2.5％～10.0％；在一些示例中，所述聚氧乙烯40氢化蓖麻油的重量百分比为5.0％～15.0％；在一些示例中，所述聚氧乙烯40氢化蓖麻油的重量百分比为10.0％～15.0％。在一些实施例中，所述聚氧乙烯40氢化蓖麻油的重量百分比为2.5％，5.0％，10.0％，或者15.0％。
所述维拉佐酮固体分散体，所述一水柠檬酸的重量百分比为2.5％～20.0％。在一些实施方式中，所述一水柠檬酸的重量百分比为2.5％～5.0％；在一些实施方式中，所述一水柠檬酸的重量百分比为2.5％～10.0％；在一些实施方式中，所述一水柠檬酸的重量百分比为5.0％～10.0％；在一些实施方式中，所述一水柠檬酸的重量百分比为5.0％～20.0％；在一些实施方式中，所述一水柠檬酸的重量百分比为10.0％～20.0％。在一些实施例中，所述一水柠檬酸的重量百分比为2.5％，5.0％，10.0％，或者20.0％。
本发明第三方面，提供一种上述维拉佐酮固体分散体的制备方法。具体方案如下：
一种上述维拉佐酮固体分散体的制备方法，包括以下步骤：按配比称取维拉佐酮、载体材料和其它物料，混合均匀，加入热熔挤出机中，挤出混合物，冷却后粉碎过筛，即得所述维拉佐酮固体分散体。
在一些实施例中，所述热熔挤出机的挤出温度为155℃～180℃；在一些实施例中，所述热熔挤出机的挤出温度为165℃～175℃。
本发明第四方面，提供上述维拉佐酮固体分散体的用途。具体方案如下：
一种上述维拉佐酮固体分散体在制备维拉佐酮制剂中的用途。所述维拉佐酮固体分散体可以与其它药学上可接受的辅料进一步制备成颗粒剂、散剂、干混悬、片剂或胶囊剂；在一些实施例中，所述片剂为包衣片。
所述药学上可接受的辅料包括但不限于以下几种：
填充剂，例如乳糖、蔗糖、果糖、低聚果糖、葡萄糖、麦芽糖、粉末糖等糖类，D-甘露醇、赤藓糖醇、木糖醇等糖醇类，玉米淀粉、马铃薯淀粉、米淀粉、部分α淀粉等淀粉类，微晶纤维素等纤维素类，硫酸钙、磷酸氢钙、碳酸钙等无机盐类；崩解剂，例如淀粉、微晶纤维素、羧甲基纤维素钙、交联羧甲基纤维素钠、交联聚维酮、羧甲基淀粉钠、低取代羟丙基纤维素等；润滑剂，例如硬脂酸镁、硬脂酸钙、硬脂酸富马酸钠、硬脂酸、滑石粉、聚乙二醇、蔗糖脂肪酸酯、微粉硅胶。
在一些实施例中，本发明将所制备的维拉佐酮固体分散体进一步地压制成片剂，并对其体内药物动力学性质进行了考察。结果显示，本发明提供的维拉佐酮固体分散体组合物能显著提高维拉佐酮在空腹条件下的生物利用度，更进一步地，能显著消除食物效应的影响，使得空腹和进食条件下服用时等效，空腹和进食条件下均可服用，显著改善患者服药的便利性，提高患者顺应性，这对于需要长期服药、且常伴有食欲不振和自杀倾向的重度抑郁症患者来说，具有重大的临床意义。
在另一些实施例中，本发明还对所制备的维拉佐酮固体分散体进行了稳定性考察，在加速条件下(40℃,75％RH)放置3个月后，所制备的维拉佐酮固体分散体仍成无定型状态，且体外溶出度无显著变化，说明本发明提供的维拉佐酮固体分散体稳定性好，适合开发成维拉佐酮固体分散体制剂并应用于临床。
术语定义
本发明意图涵盖所有的替代、修改和等同技术方案，它们均包括在如权利要求定义的本发明范围内。本领域技术人员应认识到，许多与本文所述类似或等同的方法和材料能够用于实践本发明。本发明绝不限于本文所述的方法和材料。在所结合的文献、专利和类似材料的一篇或多篇与本申请不同或相矛盾的情况下(包括但不限于所定义的术语、术语应用、所描述的技术等等)，以本申请为准。
应进一步认识到，本发明的某些特征，为清楚可见，在多个独立的实施方案中进行了描述，但也可以在单个实施例中以组合形式提供。反之，本发明的各种特征，为简洁起见，在单个实施方案中进行了描述，但也可以单独或以任意适合的子组合提供。
除非另外说明，本发明所使用的所有科技术语具有与本发明所属领域技术人员的通常理解相同的含义。本发明涉及的所有专利和公开出版物通过引用方式整体并入本发明。
术语“包含”或“包括”为开放式表达，即包括本发明所指明的内容，但并不排除其他方面的内容。
在本发明的上下文中，无论是否使用“大约”、“约”或“大概”等字眼，所有在此公开了的数字均为近似值。每一个数字的数值有可能会出现10％以下的差异或者本领域人员认为的合理的差异，如1％、2％、3％、4％或5％的差异。
LC-MS-MS指液质联用，XRD是指X射线衍射。
PVP指聚维酮，VA64指共聚维酮，HPMC指羟丙基甲基纤维素，Labrasol指辛酸癸酸聚乙二醇甘油酯，Cremophor RH40指聚氧乙烯40氢化蓖麻油，T-80指吐温-80，F68指泊洛沙姆188，S-20指司盘-20，TPGS指(D)α-生育酚聚乙二醇1000琥珀酸盐。
PEG指聚乙二醇，Soluplus指聚乙二醇/乙烯基己内酰胺/醋酸乙烯酯共聚物，HPMCAS是指醋酸羟丙甲纤维素琥珀酸酯，HPC指羟丙基纤维素。
AUC指血药浓度-时间曲线下面积，C max指达峰血药浓度。
M指摩尔，h指小时，g指克，mm指毫米，μm指微米，nm指纳米，μl指微升，min指分钟，℃指摄氏度，mg指毫克，mL指毫升，rpm指转/分钟。
附图说明
图1实施例1的(2)不同载体材料制备的维拉佐酮固体分散体的XRD图谱。
图2实施例2的(1)不同增塑剂制备的维拉佐酮固体分散体的XRD图谱。
图3实施例3的(1)不同酸试剂制备的维拉佐酮固体分散体的XRD图谱。
图4实施例5的(1)不同比例VA64制备的维拉佐酮固体分散体的XRD图谱。
图5实施例6不同挤出温度下制备的维拉佐酮固体分散体的XRD图谱。
图6对比例1盐酸维拉佐酮固体分散体的XRD图谱。
图7实施例8维拉佐酮固体分散体加速稳定性样品的XRD图谱。
具体实施方式
为了更好的理解本发明的技术方案，下面结合具体实施例对本发明作进一步的阐述。除非特别说明，在下面实施例中没有明确描述具体技术或条件的，本领域技术人员可以按照本领域内的常用技术或条件或按照产品说明书进行。所用药品、试剂或仪器未注明生产厂商者，均为可市购的常规产品。
其中，参比制剂
Figure PCTCN2019124446-appb-000013
为森林实验室开发的规格为10mg/片的盐酸维拉佐酮片。
羟丙基甲基纤维素琥珀酸酯(HPMCAS-LF和HPMCAS-MF)购于美国Ashland公司；聚乙二醇/乙烯基己内酰胺/醋酸乙烯酯共聚物(Soluplus)、聚维酮(PVP-K12)购于德国巴斯夫公司；共聚维酮(VA64)购于德国巴斯夫公司；羟丙基甲基纤维素(HPMC-E5和HPMC-LV15)购于Ashland公司；羟丙基纤维素(HPC)购于日本曹达公司。
吐温-80(T-80)、十二烷基硫酸钠(SDS)、泊洛沙姆188(F68)、泊洛沙姆477(P477)、司盘-20(S-20)、聚氧乙烯40氢化蓖麻油(Cremophor RH40)、聚氧乙烯35蓖麻油(Cremophor EL)、辛酸癸酸聚乙二醇甘油酯(Labrasol)、聚乙二醇15-羟基硬脂酸酯(Kolliphor HS15)、月桂酸聚乙二醇甘油酯(Gelucire 44/14)、月桂酸聚乙二醇甘油酯(Gelucire 50/13)、(D)α-生育酚聚乙二醇1000琥珀酸盐(TPGS)均为市售增塑剂。
维拉佐酮含量测定方法为高效液相色谱法(HPLC)，具体条件为：色谱条件：检测波长为UV 242nm，色谱柱采用kromasil 100-5 C18(4.6mm×150mm，5μm)，流动相为pH6.0的0.02M磷酸氢二钾与乙腈为 54:46(V/V)，流速为1.0ml/min，进样量为10μl，运行时间到4.5min。
实施例1不同载体材料的考察
(1)市售制剂
Figure PCTCN2019124446-appb-000014
溶出度测定
取
Figure PCTCN2019124446-appb-000015
片剂(10mg)6片，按照美国药典Ⅱ法(USPⅡ)，以900mL介质，60rpm转速为条件，分别测定在0.1M HCl、pH3.1和pH6.8介质中的溶出度。试验开始后，于5min、10min、15min、20min、30min和45min时间点取样10ml，立即补以10ml新鲜溶出介质，继续试验。将所取样品过0.45μm滤膜，取适量续滤液，用HPLC方法测定样品中药物含量，计算每个时间点的累积溶出率，具体结果见表1。
表1
Figure PCTCN2019124446-appb-000016
片剂体外溶出度测定结果
Figure PCTCN2019124446-appb-000017
(2)载体材料种类的考察
按表2中处方，称取各载体材料和维拉佐酮粉末，混合均匀，加入至热熔挤出机中，热熔挤出(挤出温度170℃，螺杆转速50rpm)，收集挤出物，冷却后粉碎，过60目筛，得到固体分散体粉末。将上述固体分散体粉末与微晶纤维素按1:2比例混合均匀，按照上述“市售制剂溶出度测定”项下方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表3。分别取上述固体分散体粉末进行X-射线粉末衍射(XRD)分析，具体结果见附图1。
表2不同载体材料筛选处方
组成 处方-1 处方-2 处方-3 处方-4
维拉佐酮 10g 10g 10g 10g
材料种类 VA64 PVP-K12 HPMCAS-MF HPMC-LV15
材料用量 60g 60g 60g 60g
泊洛沙姆188 5g 5g 5g 5g
表3不同载体材料制备的固体分散体在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000018
上述结果显示，采用共聚维酮(VA64)、聚维酮(PVP-K12)、羟丙基甲基纤维素琥珀酸酯(HPMCAS-MF)或羟丙甲纤维素(HPMC)为材料制备维拉佐酮固体分散体时，维拉佐酮均于无定型态分散于载体材料中，且其在模拟肠液(pH6.8介质)中的溶出度显著提高，远高于参比制剂
Figure PCTCN2019124446-appb-000019
的溶出度，提示维拉佐酮固体分散体可显著增加维拉佐酮在空腹条件下的口服生物利用度。
(3)混合载体材料的考察
按表4中处方，称取各载体材料、增塑剂和维拉佐酮粉末，混合均匀，加入至热熔挤出机中，热熔挤出(挤出温度180℃，螺杆转速100rpm)，收集挤出物，冷却后粉碎，过60目筛，得到固体分散体粉末。将上述固体分散体粉末与微晶纤维素按1:2比例混合均匀，按照上述“市售制剂溶出度测定”项下方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表5。
表4混合载体材料处方
组成 处方-5 处方-6 处方-7
维拉佐酮 10g 10g 10g
HPMCAS-MF 45g 30g ——
Soluplus 15g 30g ——
VA64 —— —— 30g
HPMC-E5 —— —— 30g
泊洛沙姆188 7.78g 5g 5g
表5不同混合载体材料处方固体分散体粉末在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000020
Figure PCTCN2019124446-appb-000021
上述结果显示，采用混合载体材料制备的维拉佐酮固体分散体在模拟肠液(pH6.8)中的溶出度显著高于参比制剂
Figure PCTCN2019124446-appb-000022
提示混合载体材料制备的维拉佐酮固体分散体能显著增加维拉佐酮在空腹条件下的口服生物利用度。
实施例2增塑剂的筛选
(1)共聚维酮(VA64)+不同增塑剂的考察
按表6中处方，称取维拉佐酮、共聚维酮(VA64)和各增塑剂，混合均匀，加入至热熔挤出机中，热熔挤出(挤出温度170℃，螺杆转速50rpm)，收集挤出物，冷切粉碎后，过60目筛，得到热熔粉末。将上述热熔粉末与微晶纤维素按1:2比例混合均匀，按照实施例1中(1)所述溶出度测定方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表7。另外，取少量上述热熔粉末，进行X射线粉末衍射(XRD)检测，具体结果见附图2。
表6共聚维酮+不同增塑剂处方
组成 处方-8 处方-9 处方-10 处方-11 处方-12 处方-13
维拉佐酮 10g 10g 10g 10g 10g 10g
共聚维酮 60g 60g 60g 60g 60g 60g
增塑剂 F68 PEG-6000 Labrasol TPGS RH40 Span20
用量 5g 5g 5g 5g 5g 5g
表7共聚维酮+不同增塑剂处方在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000023
上述结果显示，在共聚维酮材料基础上，加入不同种类增塑剂后，所制备的维拉佐酮固体分散体均呈 无定型态，且其溶出度显著高于参比制剂
Figure PCTCN2019124446-appb-000024
溶出度，尤其采用Labrasol和Cremophor RH40为增塑剂时，所制备的固体分散体溶出度显著增加。上述结果提示，采用不同增塑剂制备维拉佐酮固体分散体均可显著增加维拉佐酮在空腹条件下的口服生物利用度。
(2)HPMCAS-LF+不同增塑剂的考察
按表8中处方，称取HPMCSA-LF、增塑剂和维拉佐酮粉末，混合混匀，加入至挤出机中，热熔挤出(挤出温度175℃，螺杆转速150rpm)，收集挤出物，粉碎机粉碎，过60目筛，得到热熔粉末。将上述热熔粉末与微晶纤维素按1:2比例混合均匀，按照实施例1中(1)所述溶出度测定方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表9。
表8共聚维酮+不同增塑剂处方
组成 处方-14 处方-15 处方-16 处方-17
维拉佐酮 10g 10g 10g 10g
HPMCAS-LF 60g 60g 60g 60g
增塑剂 F68 Labrasol TPGS RH40
用量 5g 5g 5g 5g
表9共聚维酮+不同增塑剂处方在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000025
上述结果显示，在羟丙基甲基纤维素琥珀酸酯(HPMCAS-LF)基础上，加入不同种类增塑剂后，所制备的维拉佐酮固体分散体的溶出度显著高于参比制剂
Figure PCTCN2019124446-appb-000026
溶出度，尤其采用TPGS为增塑剂时，所制备的固体分散体溶出度显著增加。上述结果提示，采用不同增塑剂制备维拉佐酮固体分散体均可显著增加维拉佐酮在空腹条件下的口服生物利用度。
实施例3酸性试剂的筛选
(1)酸试剂种类的考察
按表10中处方，称量各载体材料、增塑剂、维拉佐酮粉末和酸性试剂，混合均匀，加入至挤出机中，热熔挤出(挤出温度170℃，螺杆转速100rpm)，收集挤出物，冷切后粉碎，过60目筛，得到热熔粉末。将上述热熔粉末与微晶纤维素按1:2比例混合均匀，按照实施例1中(1)所述溶出度测定方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表11。另外，取少量上述热熔粉末，进行X射线粉末衍射(XRD)检测，具体结果见附图3。
表10不同酸性试剂考察处方
组成 处方-18 处方-19 处方-20 处方-21 处方-22 处方-23 处方-24
维拉佐酮 10g 10g 10g 10g 10g 10g 10g
VA64 60g 60g 60g 60g 60g —— ——
PVP-12 —— —— —— —— —— 60g ——
HPMC-LV15 —— —— —— —— —— —— 60g
F68 5g 5g 5g 5g —— 5g 5g
Span20 —— —— —— —— 5g —— ——
酸试剂种类 富马酸 一水柠檬酸 L-酒石酸 琥珀酸 一水柠檬酸 一水柠檬酸 一水柠檬酸
酸试剂用量 4g 4g 4g 4g 4g 4g 4g
表11不同酸性试剂处方在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000027
上述结果显示，加入不同种类酸制剂后，所制备的维拉佐酮固体分散体均呈无定型态，其溶出度显著高于参比制剂
Figure PCTCN2019124446-appb-000028
溶出度，且显著优于未加酸性试剂处方溶出度(处方-8)。结果提示，采用不同酸 试剂制备维拉佐酮固体分散体可进一步增加维拉佐酮在空腹条件下的口服生物利用度。
(2)酸试剂用量的考察
按表12中处方，称取共聚维酮(VA64)、一水柠檬酸和维拉佐酮粉末，混合均匀；将Cremophor RH40加热熔融后，滴加至上述混合物中制粒，最后加入至挤出机中，热熔挤出(挤出温度165℃，螺杆转速50rpm)，收集挤出物，冷却后粉碎，过60目筛，得到热熔粉末。将上述热熔粉末与微晶纤维素按1:2比例混合均匀，按照实施例1中(1)所述溶出度测定方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表13。
表12不同一水柠檬酸比例的处方
组成 处方-25 处方-26 处方-27 处方-28 处方-29
维拉佐酮 10g 10g 10g 10g 10g
VA64 60g 60g 60g 60g 60g
RH40 5g 5g 5g 5g 5g
一水柠檬酸 2g 4g 8g 14g 25g
表13不同一水柠檬酸比例处方在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000029
上述结果显示，加入不同比例(2.5％～25％)的一水柠檬酸后，所制备的维拉佐酮固体分散体的体外溶出度没有显著性差异，当其比例为15％时，溶出平台相对较高。上述结果提示，采用不同比例酸试剂制备维拉佐酮固体分散体均能很好的提高其在空腹条件下的口服生物利用度。
实施例4增塑剂比例的考察
按表14中处方，称取共聚维酮(VA64)、一水柠檬酸和维拉佐酮粉末，混合均匀；再将Cremophor RH40加热熔融后，滴加至上述混合物中制粒，最后加入至挤出机中，热熔挤出(挤出温度165℃，螺杆转速50rpm)，收集挤出物，冷却后粉碎，过60目筛，得到热熔粉末。将上述热熔粉末与微晶纤维素按1:2比例混合均匀， 按照实施例1中(1)所述溶出度测定方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表15。
表14不同Cremophor RH40比例的处方
组成 处方-30 处方-31 处方-32 处方-33
维拉佐酮 10g 10g 10g 10g
VA64 60g 60g 60g 60g
RH40 2g 5g 9g 13g
一水柠檬酸 4g 4g 4g 4g
表15不同Cremophor RH40比例处方在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000030
上述结果显示，采用不同比例Cremophor RH40(2.5％～15％)制备的维拉佐酮固体分散体的体外溶出度显著高于市售制剂
Figure PCTCN2019124446-appb-000031
溶出度。上述结果提示，采用不同比例增塑剂制备维拉佐酮固体分散体均能很好的提高其在空腹条件下的口服生物利用度。
实施例5载体材料比例的考察
(1)单一载体材料用量的考察
按表16中处方，称取共聚维酮(VA64)、一水柠檬酸和维拉佐酮粉末，混合均匀；再将Cremophor RH40加热熔融后，滴加至上述混合物中制粒，最后加入至挤出机中，热熔挤出(挤出温度170℃，螺杆转速50rpm)，收集挤出物，冷却后粉碎，过60目筛，得到热熔粉末。将上述热熔粉末与微晶纤维素按1:2比例混合均匀，按照实施例1中(1)所述溶出度测定方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表17。此外，取少量上述热熔粉末，进行X射线粉末衍射(XRD)检测，具体结果见附图4。
表16不同共聚维酮(VA64)比例的处方
组成 处方-34 处方-35 处方-36 处方-37 处方-38 处方-39
维拉佐酮 10g 10g 10g 10g 10g 10g
VA64 20g 30g 40g 50g 60g 70g
RH40 1.88g 2.5g 3.12g 3.75g 5g 5g
一水柠檬酸 5.62g 7.5g 9.38g 11.25g 14g 15g
表17不同共聚维酮比例处方在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000032
上述结果显示，采用不同比例共聚维酮(VA64)制备的维拉佐酮固体分散体均成无定型态，其体外溶出度显著高于市售制剂
Figure PCTCN2019124446-appb-000033
溶出度，且随着材料用量的增加，溶出平台有增加趋势。上述结果提示，采用不同用量载体材料制备的维拉佐酮固体分散体均能很好的提高其在空腹条件下的口服生物利用度。
(2)混合载体材料比例的考察
按表18中处方，称取共聚维酮(VA64)、羟丙甲纤维素、一水柠檬酸和维拉佐酮粉末，混合均匀；再将Cremophor RH40加热熔融后，滴加至上述混合物中制粒，最后加入至挤出机中，热熔挤出(挤出温度175℃，螺杆转速100rpm)，收集挤出物，冷却后粉碎，过60目筛，得到热熔粉末。将上述热熔粉末与微晶纤维素按1:2比例混合均匀，按照实施例1中(1)所述溶出度测定方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表19。
表18不同比例混合载体材料处方
组成 处方-40 处方-41 处方-42
维拉佐酮 10g 10g 10g
VA64 30g 40g 48g
HPMC-LV15 30g 10g 12g
RH40 5g 5g 5g
一水柠檬酸 4g 4g 4g
表19不同比例混合载体处方在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000034
上述结果显示，采用不同比例的混合载体材料制备维拉佐酮固体分散体时，所制备的固体分散体在模拟肠液(pH6.8介质)中的溶出度显著高于参比制剂
Figure PCTCN2019124446-appb-000035
提示不同比例混合材料制备的维拉佐酮固体分散体能显著增加维拉佐酮在空腹条件下的口服生物利用度。
实施例6热熔挤出温度的考察
按表20中处方，称取共聚维酮(VA64)、一水柠檬酸和维拉佐酮粉末，混合均匀；再将Cremophor RH40加热熔融后，滴加至上述混合物中制粒，最后加入至挤出机中，热熔挤出(螺杆转速100rpm)，分别考察不同的挤出温度(175℃、165℃、155℃)的影响，收集挤出物，冷却后粉碎，过60目筛，得到热熔粉末。将上述热熔粉末与微晶纤维素按1:2比例混合均匀，按照实施例1中(1)所述溶出度测定方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表21。分别取上述热熔粉末进行X-射线粉末衍射(XRD)分析，具体结果见附图5。
表20不同挤出温度处方
组成 处方-43 处方-44 处方-45
维拉佐酮 10g 10g 10g
VA64 60g 60g 60g
RH40 5g 5g 5g
一水柠檬酸 14g 14g 14g
热熔挤出温度 175℃ 165℃ 155℃
表21不同挤出温度处方在在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000036
上述结果显示，采用不同挤出温度(155℃～175℃)制备维拉佐酮固体分散体时，维拉佐酮均于无定型态分散于载体材料中，且其在模拟肠液(pH6.8介质)中的溶出度显著提高，远高于参比制剂
Figure PCTCN2019124446-appb-000037
的溶出度，提示维拉佐酮固体分散体可显著增加维拉佐酮在空腹条件下的口服生物利用度。
对比例1盐酸维拉佐酮固体分散体的制备
按表22中处方，称取各载体材料和盐酸维拉佐酮粉末，混合均匀，加入至热熔挤出机中，热熔挤出(挤出温度180℃，螺杆转速50rpm)，收集挤出物，冷却后粉碎，过60目筛，得到固体分散体粉末。将上述固体分散体粉末与微晶纤维素按1:2比例混合均匀，按照上述“市售制剂溶出度测定”项下方法，检测10mg规格样品在pH6.8介质中的溶出度，结果见表23。分别取上述固体分散体粉末进行X-射线粉末衍射(XRD)分析，具体结果见附图6。
表22不同载体材料处方
组成 处方-46 处方-47 处方-48
盐酸维拉佐酮 15g 15g 15g
VA64 60g —— 60g
Soluplus —— 60g 30g
泊洛沙姆188 5g 5g 5g
表23不同载体材料制备的盐酸维拉佐酮固体分散体在pH6.8介质中的溶出度
时间 5min 10min 15min 20min 30min 45min 60min
处方-46 26±3.54 31±1.41 33±0.00 25±3.54 31±1.41 33±0.71 33±1.21
处方-47 20±10.97 24±4.04 23±3.61 25±6.66 24±1.00 26±1.53 29±1.06
处方-48 11±2.08 16±1.53 19±1.00 21±1.00 24±1.53 28±1.15 28±0.85
结果显示，采用热熔挤出工艺制备的盐酸维拉佐酮固体分散体均为混晶状态(XRD图谱)，挤出物中仍含有晶型药物，且其体外溶出度显著低于无定型的维拉佐酮固体分散体。上述结果提示，采用更低溶解度 的维拉佐酮游离碱，通过热熔挤出工艺制备成无定型固体分散体后，能意想不到的提高维拉佐酮的体外溶解性和体内生物利用度。
实施例7 Beagle犬体内药物动力学性质考察
(1)维拉佐酮片剂的制备
选用处方18的热熔挤出粉末为原料，按表24称量各物料，混合均匀；总混物料过40目筛，直接压片，即得盐酸维拉佐酮片剂。
(2)Beagle犬体内药物动力学实验
采用上述盐酸维拉佐酮片剂(10mg规格)进行Beagel犬体内药动试验的考察。6只雄性、健康成年Beagle犬，体重范围为15～20kg，随机分为2组，进行双交叉、两周期试验，分别考察自研维拉佐酮片剂(10mg)在空腹、进食(高脂、高热量食物)条件下的药动学性质。动物口服给药后，分别于0.25、0.5、1、2、4、6、8、10、24h时间点采取全血；将上述全血置于盛有K 2EDTA抗凝剂的离心管中，4℃条件下，3500转/分钟离心10min，收集上层血浆，-70℃条件下保存，待检测。
采用LC-MS-MS方法检测血浆中维拉佐酮的含量，应用WinNonlin 6.3软件非房室模型法计算药动学参数。(备注：Fast代表空腹给药，Fed代表进食给药；Test为自研维拉佐酮片剂，RLD为参比制剂
Figure PCTCN2019124446-appb-000038
)
食物效应评价标准按照Ratio计算，即Ratio＝Fed/Fast*100％，具体结果见表25(参比制剂
Figure PCTCN2019124446-appb-000039
的动物体内PK数据参考优先权专利WO2018082557A1)。对于给定的受试动物群中的单只动物均按此公式计算Cmax和AUC的Ratio值，每只动物的Ratio值相加后，将总和除以受试动物只数，即得平均值。如果Ratio均值在大约70％到大约143％范围内，即可确定该剂型没有食物效应，进食和空腹服用时是等效的，也就是说，该剂型无论是在进食或空腹条件下服用，均具有基本相同的生物利用度和药效。
表24维拉佐酮片剂处方
Figure PCTCN2019124446-appb-000040
Figure PCTCN2019124446-appb-000041
表25空腹和进表25进食状态下维拉佐酮片剂药动学数据(Mean,n＝6)
Figure PCTCN2019124446-appb-000042
上述结果显示，自制维拉佐酮组合物片剂在进食(Test–fed)和空腹(Test-fast)状态下的Cmax和AUC接近，Ratio均值均在70％～143％范围内，认为没有食物效应，说明本实施例提供的维拉佐酮固体分散体制备制剂可显著提高维拉佐酮空腹状态下的生物利用度，消除食物的影响，使空腹和进食状态下均可服用药物；而市售制剂
Figure PCTCN2019124446-appb-000043
(RLD,10mg)在进食和空腹状态下Cmax和AUC比值远远大于70％～143％范围，存在显著的食物效应。上述结果提示本发明提供的维拉佐酮固体分散体制剂可显著提高维拉佐酮空腹服用时的生物利用度，消除了食物的影响，空腹和进食条件下均可服用，显著改善患者服药的便利性，提高患者顺应性，这对于需要长期服药、且常伴有食欲不振和自杀倾向的重度抑郁症患者来说，具有重大的临床意义。
实施例8加速稳定性考察
取适量处方22和处方31的热熔粉末，于双铝袋中密封包装，在40℃、75％RH(湿度)条件下，储存3个月；到达时间点后，取样，分别测定各个处方中维拉佐酮的晶型以及体外pH6.8介质中的溶出度。各个处方喷干粉末样品储存3个月后的XRD粉末衍射图谱见附图7，溶出度结果见表26。结果显示，不同处方制备的维拉佐酮固体分散体在加速条件下储存3个月后，仍然于非晶形态分散于载体材料中，且体外溶出度未下降，提示本发明提供的维拉佐酮固体分散体稳定性良好。
表26不同处方喷干粉末在pH6.8介质中的溶出度结果
Figure PCTCN2019124446-appb-000044
以上所述实施例的各技术特征可以进行任意的组合，为使描述简洁，未对上述实施例中各技术特征所有可能的组合进行描述；然而，只要这些技术特征的组合不存在矛盾，都应该被认为属于本发明说明书记载的范围。以上实施例仅表达了本发明的几种实施方式，其描述较为具体，但并不能理解为对本发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。

Claims (31)

  1. 一种维拉佐酮固体分散体，其特征在于，包含维拉佐酮、载体材料和增塑剂。
  2. 根据权利要求1所述的维拉佐酮固体分散体，其特征在于，所述载体材料为水溶性载体材料。
  3. 根据权利要求2所述的维拉佐酮固体分散体，其特征在于，所述水溶性载体材料包括选自聚维酮、共聚维酮、羟丙基甲基纤维素、羟丙甲纤维素琥珀酸酯中的至少一种。
  4. 根据权利要求3所述的维拉佐酮固体分散体，其特征在于，所述水溶性载体材料为共聚维酮。
  5. 根据权利要求1所述的维拉佐酮固体分散体，其特征在于，所述维拉佐酮与载体材料的重量比不大于1:2。
  6. 根据权利要求5所述的维拉佐酮固体分散体，其特征在于，所述维拉佐酮与载体材料的重量比为1:2～1:7。
  7. 根据权利要求5所述的维拉佐酮固体分散体，其特征在于，所述维拉佐酮与载体材料的重量比为1:4～1:6。
  8. 根据权利要求1所述的维拉佐酮固体分散体，其特征在于，所述增塑剂包括选自司盘-20、聚乙二醇、聚氧乙烯氢化蓖麻油、辛酸癸酸聚乙二醇甘油酯、泊洛沙姆、α-生育酚聚乙二醇琥珀酸盐中的至少一种。
  9. 根据权利要求8所述的维拉佐酮固体分散体，其特征在于，所述增塑剂包括选自聚氧乙烯40氢化蓖麻油、辛酸癸酸聚乙二醇甘油酯、(D)α-生育酚聚乙二醇1000琥珀酸盐中的至少一种。
  10. 根据权利要求9所述的维拉佐酮固体分散体，其特征在于，所述增塑剂为聚氧乙烯40氢化蓖麻油。
  11. 根据权利要求1所述的维拉佐酮固体分散体，其特征在于，所述增塑剂的重量百分比不小于2.5％。
  12. 根据权利要求11所述的维拉佐酮固体分散体，其特征在于，所述增塑剂的重量百分比为2.5％～15.0％。
  13. 根据权利要求11所述的维拉佐酮固体分散体，其特征在于，所述增塑剂的重量百分比为5.0％～10.0％。
  14. 根据权利要求1所述的维拉佐酮固体分散体，其特征在于，所述固体分散体还包括酸性试剂。
  15. 根据权利要求14所述的维拉佐酮固体分散体，其特征在于，所述酸性试剂包括选自富马酸、一水柠檬酸、柠檬酸或L-酒石酸中的至少一种。
  16. 根据权利要求15所述的维拉佐酮固体分散体，其特征在于，所述酸性试剂为一水柠檬酸。
  17. 根据权利要求14所述的维拉佐酮固体分散体，其特征在于，所述酸性试剂的重量百分比不小于2.5％。
  18. 根据权利要求17所述的维拉佐酮固体分散体，其特征在于，所述酸性试剂的重量百分比为2.5％～25.0％。
  19. 根据权利要求17所述的维拉佐酮固体分散体，其特征在于，所述酸性试剂的重量百分比为5.0％。
  20. 一种维拉佐酮固体分散体，其特征在于，包含维拉佐酮、共聚维酮、聚氧乙烯40氢化蓖麻油和一水柠檬酸。
  21. 根据权利要求20所述的维拉佐酮固体分散体，其特征在于，所述维拉佐酮与所述共聚维酮的重量比为1:3～1:6。
  22. 根据权利要求20所述的维拉佐酮固体分散体，其特征在于，所述聚氧乙烯40氢化蓖麻油的重量百分比为2.5％～15.0％。
  23. 根据权利要求20所述的维拉佐酮固体分散体，其特征在于，所述聚氧乙烯40氢化蓖麻油的重量百分比为5.0％～10.0％。
  24. 根据权利要求20所述的维拉佐酮固体分散体，其特征在于，所述一水柠檬酸的重量百分比为2.5％～20.0％。
  25. 根据权利要求1-24任一项所述的维拉佐酮固体分散体，其特征在于，所述维拉佐酮为游离碱形式。
  26. 一种制备权利要求1-24任一项所述的维拉佐酮固体分散体的方法，其特征在于，包括以下步骤：
    按配比称取维拉佐酮、载体材料和其它物料，混合均匀后，加入热熔挤出机中，挤出混合物，冷却后粉碎，及得所述维拉佐酮固体分散体。
  27. 根据权利要求26所述的制备方法，其特征在于，所述热熔挤出的挤出温度为155℃～180℃。
  28. 根据权利要求26所述的制备方法，其特征在于，所述热熔挤出的挤出温度为165℃～175℃。
  29. 一种权利要求1-24任一项所述的维拉佐酮固体分散体在制备维拉佐酮制剂中的用途。
  30. 根据权利要求29所述的用途，其特征在于，所述维拉佐酮制剂的剂型包括颗粒剂、散剂、干混悬、片剂或胶囊剂。
  31. 根据权利要求30所述的用途，其特征在于，所述片剂为包衣片。
PCT/CN2019/124446 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法 WO2020119701A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980080339.8A CN113164394B (zh) 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811523043.2 2018-12-13
CN201811523043 2018-12-13

Publications (1)

Publication Number Publication Date
WO2020119701A1 true WO2020119701A1 (zh) 2020-06-18

Family

ID=71075886

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2019/124429 WO2020119698A1 (zh) 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法
PCT/CN2019/124446 WO2020119701A1 (zh) 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/124429 WO2020119698A1 (zh) 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法

Country Status (3)

Country Link
US (1) US20220071993A1 (zh)
CN (2) CN113164473B (zh)
WO (2) WO2020119698A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023179774A1 (en) * 2022-03-25 2023-09-28 Shenzhen Pharmacin Co., Ltd. Amorphous solid dispersions and pharmaceutical compositions comprising the same
CN115581678B (zh) * 2022-11-04 2023-09-12 北京鑫开元医药科技有限公司 一种瑞派替尼片组合物及其制备方法
CN117257804A (zh) * 2023-10-17 2023-12-22 深圳市新阳唯康科技有限公司 达拉非尼药物组合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
CN103211751A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 含维拉唑酮的药物组合物及其制备方法
WO2013168126A1 (en) * 2012-05-11 2013-11-14 Dr.Reddys Laboratories Limited Crystalline forms of vilazodone hydrochloride and vilazodone free base
CN104523620A (zh) * 2014-12-14 2015-04-22 天津市康瑞药业有限公司 维拉佐酮滴丸及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078361A1 (en) * 2011-11-23 2013-05-30 Assia Chemical Industries Ltd. Solid state forms of vilazodone and vilazodone hydrochloride
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
CN104116741B (zh) * 2013-04-24 2019-06-11 江苏先声药业有限公司 盐酸维拉佐酮组合物及其制备方法
IN2013MU03458A (zh) * 2013-10-31 2015-07-17 Lupin Ltd
CN106540266A (zh) * 2015-09-18 2017-03-29 天津市汉康医药生物技术有限公司 一种维拉佐酮药物组合物及其制备方法
CN106580895A (zh) * 2016-12-07 2017-04-26 万全万特制药（厦门）有限公司 含盐酸维拉佐酮固体分散体的口腔崩解片及其制备方法
US11090272B2 (en) * 2017-01-06 2021-08-17 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof
CN106580914A (zh) * 2017-02-27 2017-04-26 佛山市弘泰药物研发有限公司 一种盐酸维拉佐酮软胶囊及其制备方法
CN108078934B (zh) * 2017-12-26 2020-08-28 南京工业大学 一种盐酸齐拉西酮固体分散片及其热熔挤出方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
WO2013168126A1 (en) * 2012-05-11 2013-11-14 Dr.Reddys Laboratories Limited Crystalline forms of vilazodone hydrochloride and vilazodone free base
CN103211751A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 含维拉唑酮的药物组合物及其制备方法
CN104523620A (zh) * 2014-12-14 2015-04-22 天津市康瑞药业有限公司 维拉佐酮滴丸及其制备方法

Also Published As

Publication number Publication date
WO2020119698A1 (zh) 2020-06-18
CN113164473B (zh) 2024-08-23
CN113164394A (zh) 2021-07-23
US20220071993A1 (en) 2022-03-10
CN113164394B (zh) 2023-06-23
CN113164473A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US20230122911A1 (en) Formulations of enzalutamide
WO2020119701A1 (zh) 一种维拉佐酮固体分散体及其制备方法
WO2015154718A1 (zh) 泊沙康唑药物组合物及其制备方法、应用和药物制剂
US20100143459A1 (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US20090203709A1 (en) Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
US8663698B2 (en) Solid dispersion preparation
BRPI0718521A2 (pt) Forma de dosagem, e, métodos para tratar distúrbios proliferativos, e para preparar a forma de dosagem
US20070248682A1 (en) Solid preparation comprising enteric solid dispersion
US7736672B2 (en) Multiparticulate compositions with improved stability
JP2011530532A (ja) 固体分子分散物中のｈｃｖプロテアーゼインヒビターの薬学的処方物
US20210251985A1 (en) Lurasidone solid dispersion and preparation method thereof
US20160000720A1 (en) Pharmaceutical compositions comprising Tadalafil
US20150157628A1 (en) Pharmaceutical compositions of Lurasidone and Process for preparation thereof
CN113018290A (zh) 一种紫杉醇药物组合物及其药物制剂、制备方法和用途
CN113350290A (zh) 一种阿瑞匹坦固体分散组合物及其制备方法
CN109125320B (zh) 一种吡啶类化合物的药物组合物
CN114533735A (zh) 盐酸鲁拉西酮药物组合物及其制备方法
CN114948960A (zh) 一种维拉佐酮的组合物及其制备方法
CA3160834A1 (en) Amorphous pharmaceutical compositions of abiraterone acetate
WO2015163689A1 (ko) 활성 성분 (i) 함유 조성물 및 이의 제조 방법
MXPA06006034A (en) Multiparticulate compositions with improved stability

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19895316

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19895316

Country of ref document: EP

Kind code of ref document: A1